We are at a breakthrough moment for Alzheimer’s disease research and drug development. At Acumen, we are leveraging decades of learnings to deliver treatments that can truly impact everyone affected by this devastating disease.
Alzheimer’s disease (AD) currently affects over 6 million people in the U.S. and approximately 32 million people worldwide. By 2050, these numbers are expected to roughly triple and healthcare costs in the U.S. alone will exceed 1 trillion dollars without effective measures to prevent or slow the disease. AD is now the sixth-leading cause of death in the U.S., and it is likely to continue rising in the absence of more efficacious treatments.
AT ACUMEN, WE ARE SINGULARLY FOCUSED ON DEVELOPING TARGETED THERAPIES FOR A DISEASE THAT HAS REMAINED UNTREATABLE FOR FAR TOO LONG.
We are advancing ACU193, a therapeutic candidate designed to have disease-modifying benefits with an improved safety profile, while also potentially providing symptomatic benefit for AD patients. ACU193 is the first immunotherapy drug candidate to enter the clinic that was developed to target toxic amyloid-beta oligomers (AβOs): a persistent driver of Alzheimer’s-associated pathology and neurodegeneration.
Our founders pioneered the seminal discoveries and methods to understand the role of AβOs in synaptic dysfunction and neurodegeneration. Today, Acumen’s leaders, including former senior members of Eli Lilly’s global Alzheimer’s disease platform team, are leveraging these critical insights to advance ACU193 into the clinic and beyond.
Acumen’s team is made up of neuroscientists, Alzheimer’s therapy developers and industry leaders with decades of experience across the field. Capitalizing on collective learnings in the space, we aspire to deliver treatments that can substantially impact outcomes—for patients, their families and society.
